Aphidicolin

Drug Profile

Aphidicolin

Alternative Names: Aphidicolin glycinate ester; Aphydicolin; Bellinzona; EM 85/061; ICI 137233; NSC 303812

Latest Information Update: 18 Jun 1999

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Cancer Institute (USA); Nonindustrial source; Pembury Hospital; SuperGen
  • Class Cytostatic antibiotics
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Herpesvirus infections

Most Recent Events

  • 18 Jun 1999 Discontinued-Preclinical for Herpesvirus infections in USA (Unknown route)
  • 18 Jun 1999 Discontinued-I for Cancer in USA (IV-infusion)
  • 18 Jun 1999 Discontinued-I for Cancer in Switzerland (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top